Condition: Prostate Adenocarcinoma · Sponsor: University of Texas Southwestern Medical Center
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
This description comes directly from the study's public registry record.
Sarah Neufeld · 214-645-8525 · Sarah.hardee@utsouthwestern.edu
Liliana Robles · 214-645-8525 · liliana.robles@utsouthwestern.edu
Always discuss trial participation with your own doctor first.
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06044857